Skip to content
Screener

MaxCyte MXCT Q4 2025 Annual earnings

Reported March 24, 2026 · After market close

Revenue$7.3MMiss by $1.8M
EPS-$0.06Beat by $0.02
Revenue estimate$9.1M
EPS estimate-$0.08

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$7.0M
EPS estimate-$0.08

Financials

Q4 2025

Income statement

See full
Revenue$7.3M-16.0%
Gross profit$5.7M-11.3%
Operating income-$11.2M+13.0%
Net income-$9.6M+9.4%
EPS (diluted)-$0.09+10.0%

Balance sheet

See full
Cash & equivalents$20.1M-28.0%
Total debt$17.9M-0.5%
Total equity$171.5M-16.9%
Total assets$202.5M-15.4%

Cash flow

See full
Operating cash flow-$2.7M+65.6%
CapEx$231.0K+57.1%
Free cash flow-$2.9M+63.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$165.34M-62.3%
Enterprise value$163.22M-61.9%
P/S5×-6.4×

Profitability

See full
Gross margin81.2%-0.5pp
Operating margin-157.1%+35.8pp
Net margin-135.1%+50.4pp
FCF margin-109.5%+88.2pp

Returns & leverage

See full
Return on equity-23.6%+8.4pp
Debt / equity0.1×0.0×
Current ratio8.3×-2.6×

Segments

By product

See full
License$2.5M-3.8%
Assay And Other Service Revenue$609.0K—

By segment

See full
Cell Engineering Technology$7.3M-16.0%

FAQ

When did MaxCyte report Q4 2025 earnings?
MaxCyte (MXCT) reported Q4 2025 earnings on March 24, 2026 after market close.
What were MaxCyte's Q4 2025 revenue and EPS?
MaxCyte reported revenue of $7.3M and eps of $-0.06 for Q4 2025.
Did MaxCyte beat estimates in Q4 2025?
Revenue missed the consensus estimate of $9.1M by $1.8M. EPS beat the consensus estimate of $-0.08 by $0.02.
How did MaxCyte's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 16.0% from $8.7M a year earlier and eps grew 40.0% from $-0.10.
Where can I find MaxCyte's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-033867) and the 10-K periodic report (0001104659-26-034557) directly on SEC EDGAR. The filing index links above go to sec.gov.